Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the combination of pembrolizumab and enfortumab vedotin for use both before and after surgical removal of the bladder. The approval covers patients regardless of whether they can tolerate cisplatin-based chemotherapy, a distinction that could reshape how oncologists approach one of the most aggressive forms of the disease. The decision, built on results from a randomized phase 3 trial, positions an immunotherapy-plus-antibody-drug-conjugate pairing as a direct alternative to the decades-old cisplatin regimen that many patients either cannot receive or struggle to complete.
A chemotherapy-free path for bladder cancer surgery patients
The central tension in this approval is practical: cisplatin-based chemotherapy has been the standard perioperative treatment for muscle-invasive bladder cancer for years, yet a significant share of patients are ineligible for it because of kidney dysfunction, hearing loss, heart failure, or other conditions. Even among those who qualify, tolerability remains a persistent barrier. By clearing pembrolizumab (sold as Keytruda and the subcutaneous Keytruda Qlex formulation) alongside enfortumab vedotin (Padcev) for perioperative use, the FDA effectively gave oncologists a regimen that does not depend on cisplatin eligibility at all.
The hypothesis worth tracking is whether this broader access will measurably reduce cisplatin utilization rates in muscle-invasive bladder cancer over the next 18 months. If the new regimen gains traction among both cisplatin-eligible and cisplatin-ineligible patients, insurance claims data stratified by eligibility status should show a detectable shift. That shift would signal more than a change in prescribing habits. It would mark a structural move away from platinum-based chemotherapy as the default perioperative backbone for this cancer.
The FDA had already taken a step in this direction. Earlier, the agency approved the same Keytruda-plus-Padcev combination specifically for patients who were ineligible for cisplatin or who declined it. That decision, based on the KEYNOTE-905/EV-303 trial (NCT03924895), compared the combination against radical cystectomy alone and demonstrated gains in event-free survival and overall survival. The July 2026 clearance extends the indication to cisplatin-eligible patients as well, a much larger population, and aligns perioperative management across eligibility categories.
KEYNOTE-B15 trial data and the cisplatin-eligible expansion
The July 2026 approval rests on a different evidence base than the earlier cisplatin-ineligible clearance. According to the FDA, the pivotal trial behind the new indication is KEYNOTE-B15, also known as EV-304 (NCT04700124). This randomized phase 3 study enrolled cisplatin-eligible adults with muscle-invasive bladder cancer and compared perioperative enfortumab vedotin plus pembrolizumab against standard neoadjuvant chemotherapy with gemcitabine and cisplatin. The primary endpoint was event-free survival, with overall survival and pathologic complete response as key secondary outcomes.
The trial design itself carries weight. Where the earlier KEYNOTE-905/EV-303 study measured the combination against surgery alone in patients who could not receive cisplatin, KEYNOTE-B15 tested it head-to-head against the existing chemotherapy standard in patients who could tolerate cisplatin. That distinction matters because it directly addresses whether the new regimen can replace, not just supplement, the current standard of care for the broadest eligible population. Demonstrating superiority or at least noninferiority to gemcitabine plus cisplatin in this setting is what allows regulators to treat the combination as a true alternative rather than a niche option.
The FDA’s oncology approvals log, which records the July 10, 2026 authorization and perioperative indication, confirms the scope: neoadjuvant use before surgery followed by adjuvant use after cystectomy. The approved label on DailyMed details dosing schedules, monitoring requirements, and safety warnings for the perioperative regimen, including immune-related adverse events associated with pembrolizumab and neuropathy and skin reactions linked to enfortumab vedotin. Prescribing information references the EV-304 evaluation within the labeling sections, linking the drug’s full safety profile to its clinical trial record and providing oncologists with the data needed to weigh risks against potential survival gains.
Clinically, the combination aims to attack the tumor on two fronts. Pembrolizumab, a PD-1–blocking antibody, is designed to reinvigorate exhausted T cells and sustain an immune response against bladder cancer cells. Enfortumab vedotin, an antibody-drug conjugate targeting Nectin-4, delivers a microtubule-disrupting agent directly to tumor cells expressing that surface protein. In the perioperative context, this dual mechanism is intended first to shrink or eradicate micrometastatic disease before surgery and then to mop up residual cancer cells afterward, potentially reducing the likelihood of recurrence.
Implications for practice and patient selection
For clinicians, the immediate question is how to integrate this option into treatment pathways that have long centered on cisplatin. One likely pattern is that cisplatin-ineligible patients will continue to move rapidly toward the combination, given its earlier approval in that group and the lack of other proven perioperative strategies. For cisplatin-eligible patients, adoption may be more gradual as multidisciplinary teams compare survival outcomes, toxicity profiles, and patient preferences.
Some oncologists may reserve the new regimen for patients who are technically cisplatin-eligible but borderline in terms of renal function or comorbidities, seeing it as a way to avoid the cumulative toxicities of platinum therapy. Others may prioritize it for patients who are highly motivated to pursue an immunotherapy-based approach, particularly if they have concerns about long-term hearing loss or neuropathy associated with cisplatin. Shared decision-making discussions will likely focus on the trade-offs between the better-characterized risks of chemotherapy and the immune-related toxicities of pembrolizumab, which can include endocrinopathies, colitis, and pneumonitis.
Health systems and payers will also influence how quickly practice patterns shift. The combination involves two branded biologic agents, and its cost relative to generic chemotherapies is substantial. Payers may require documentation of cisplatin eligibility or ineligibility, or prior authorization reflecting multidisciplinary review, before approving perioperative use. Over time, real-world outcomes data-captured in registries and claims analyses-will help clarify whether the survival benefits observed in clinical trials translate into routine practice and justify broad coverage.
International context and regulatory momentum
Across the Atlantic, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued an opinion on a related variation for Keytruda plus enfortumab vedotin in resectable muscle-invasive bladder cancer for cisplatin-ineligible patients. A final European Commission decision on that variation has not yet been confirmed, but the CHMP opinion offers an early international benchmark for how regulators outside the United States are evaluating the perioperative role of this combination. If the European decision aligns with the U.S. approach, it could accelerate harmonization of treatment standards and facilitate cross-border clinical research on optimal sequencing and duration.
Global regulatory convergence would also make it easier to design future trials that explore de-escalation strategies, such as shortening the duration of adjuvant therapy for patients who achieve deep responses, or escalation strategies for those with high-risk features on surgical pathology. As more data emerge, guidelines committees will revisit recommendations on staging workup, biomarker use, and surveillance imaging in patients treated with immunotherapy-based perioperative regimens.
What to watch next
Several questions will shape how transformative this approval ultimately becomes. One is whether biomarkers-such as PD-L1 expression, tumor mutational burden, or circulating tumor DNA-can identify patients who derive the greatest benefit from pembrolizumab plus enfortumab vedotin and those who might safely stick with cisplatin-based chemotherapy. Another is how the regimen performs in specific subgroups, including patients with variant histologies, older adults with frailty, and those with borderline organ function.
Longer-term follow-up from KEYNOTE-B15 will be critical to understanding durability of benefit, patterns of relapse, and late-onset toxicities. Meanwhile, ongoing real-world studies will test whether the survival gains seen in controlled trial settings hold up in community oncology practices, where patients often have more comorbidities and less intensive monitoring. If the data remain favorable, the July 2026 decision could mark the inflection point at which perioperative management of muscle-invasive bladder cancer begins to pivot away from a chemotherapy-first paradigm toward a more immunotherapy-centered standard of care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
